ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1872

Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study

Fahidah Alenzi1, Shirish Sangle2 and Sanna Giovanni2, 1Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, 2Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Meeting: ACR Convergence 2022

Keywords: B-Cell Targets, dermatomyositis, Myositis, Outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Idiopathic inflammatory myositis (IIM) includes a spectrum of a rare autoimmune disease characterized by proximal muscle weakness, variable skin manifestation and extra muscular manifestations. Rituximab has been shown to be effective in refractory IIM. The aim was to describe myositis specific autoantibodies (MSA) associated clinical and laboratory characteristics including B cell depletion and ability to reduce steroid requirement in patients with IIM following rituximab treatment.

Methods: MSA associated clinical and laboratory data were retrospectively collected on IIM patients attending our Lupus Unit at Guy’s and St Thomas’ Trust between 2018 and 2021. We included 32 patients with refractory IIM (15 antisynthetase syndrome,17 myositis with other MSA), who received rituximab after failing to respond to multiple immunosuppressive drugs including cyclophosphamide. Numeric response variables (median and range) including age, disease duration, follow up duration, CK level pre and post treatment, albumin, inflammatory markers, immunoglobulins and degree of B cell count depletion at baseline, 6 months and 12 months following rituximab and MMT8 were collected. Frequencies and percentages categorical variables including gender, ethnicity, clinical manifestations, type of MSA, ability to reduce steroids,immunosuppression therapy used and patients’ outcomes following rituximab use (clinically stable versus active) were analyzed.

Results: 53% were female and 47% male, with a median age of 49.5 (21-72) years. Median disease duration was 6-year and median follow up 7 years. Anti-synthetase syndrome was diagnosed in 15 patients (46.9%), and 17 (53.1%) had myositis with other MSA.12 patients (37.5%) had ILD with organizing pneumonia , 8 (25%) had ILD with NSIP, 1(3.1%) had ILD with UIP, 4 (12.5%) had mixed OP-NSIP, and 3 (9.4%) had no ILD. 6 (18.8%) had cardiac involvement, 18 (56.3%) had variable skin manifestations, 3 (9.4%) had dysphagia, 26 (81.3%) arthritis, and 27 (84.4%) muscle weakness. Twenty-six patients (81.3%) responded well to treatment and achieved clinically stable disease, while 6 patients (18.8%) remained with active myositis. Out of 15 patients with anti-synthetase syndrome,11 (73.3%) reached a stable clinical outcome and 4 patients (26.7%) remained with active disease. Patients positive for anti-SAE, MDA5, Ku, or EJ, achieved a 100% response. Median CK level pre-rituximab treatment was 1612 (45-24045) IU/L, and 124.5 (35-7287) IU/L post-rituximab. Five patients (15.6%) had albumin levels less than 40 mg/dl, 4 (80%) had active disease, and 1 (20%) had a stable outcome (p< 0.01). In total, 24 (75.5%) patients were able to reduce the prednisolone < 7.5 mg daily, with 23 (95.8%) achieving a stable outcome. The median B cell count at baseline was 137.5 (9-961) cls/ml, with 1.5 (0-12) cls/ml at 6 months and 10 (0-677) cls/ml at 12 months post rituximab treatment.

Conclusion: Over 80% of our IIM patients reached clinical remission following treatment with rituximab and 75.5 % were able to significantly reduce steroid dose maintenance. Further prospective studies with larger sample sizes and longer follow-up are needed to estimate IIM outcomes after rituximab therapy.

Supporting image 1


Disclosures: F. Alenzi, None; S. Sangle, None; S. Giovanni, None.

To cite this abstract in AMA style:

Alenzi F, Sangle S, Giovanni S. Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/outcome-of-idiopathic-inflammatory-myositis-patients-who-received-rituximab-a-single-centre-retrospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcome-of-idiopathic-inflammatory-myositis-patients-who-received-rituximab-a-single-centre-retrospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology